Advancements in Ichthyosis Treatment in Pediatric Patients: Evaluating the Impact of Immune System Inhibitors Targeting TNF-alpha, IL-17A, IL-4, and IL-12
DOI:
https://doi.org/10.54536/ajlsi.v3i1.2730Keywords:
Ichthyosis, Secukinumab, Pediatrics, IL-17, TNF-alpha, IL-4, IL-12Abstract
Lamellar, X-linked recessive, and Vulgaris ichthyosis represent rare genetic variants distinguished by abundant dry surface scales. The etiology of childhood ichthyosis involves a combination of acquired and inherited factors. Children with Ichthyosis have a Th17-dominant immune profile, similar to psoriasis, with a correlation between ichthyosis severity, erythema, Trans Epidermal Water Loss (TEWL), and immunological markers. In order to examine the safety and effectiveness of immune system inhibitors that target TNF-alpha, IL-17A, IL-4, and IL-12 in the treatment of pediatric Ichthyosis, a retrospective research study was conducted on 30 pediatric patients aged 6-12 years at tertiary care pediatric dermatology hospitals in UAE, for a time duration of 5 months. IL-17-A is a key cytokine of Ichthyosis, and its specific suppression is considered necessary in contrast to other cytokines. Consequently, the choice of treatment was dictated by elements unique to the condition and the intensity of symptoms, focusing on using Secukinumab as an IL-17-A inhibitor. The findings showed that, following five months of treatment, patients receiving secukinumab showed positive outcomes, with their ichthyosis area severity index score declining by 45 to 50%. Additionally, the proinflammatory rate of cytokines was significantly lower in this group of patients compared to the placebo-treated control group. The safety and Efficacy of Secukinumab compared to Ixekizumab and Brodalumab vs placebo were examined using t-tests, with statistical significance determined at P< 0.05. The present research study concludes that Secukinumab effectively enhances skin texture and reduces scaling severity in Ichthyosis, suggesting clinical relevance. The findings underscore Secukinumab’s potential as a beneficial agent for various ichthyosis types, such as lamellar, X-linked, and vulgaris. The study’s comparison with placebo and other IL-17A inhibitors like Ixekizumab and Brodalumab provides valuable insights into Secukinumab’s Efficacy and potential clinical uses.
Downloads
References
Afshan, T., & Kelbel, T. (2019). M501 An Adolescent Patient With Krt10 Mutation-Associated Ichthyosis Successfully Treated With Dupilumab. Annals of Allergy, Asthma & Immunology, 123(5), S139.
Albela, H., Ingrid Pao Lin, T., Lee, T. S., Ooi, D., & Leong, K. F. (2024). Secukinumab therapy for paediatric patients with various phenotypes of congenital ichthyosis. Clinical and experimental dermatology, llae082.
Almuhanna, N., Alasmari, B. S., Alhamazani, R., Alkhezzi, S., Alhomida, F. A., Alasmari, B., & Alshammari, R. (2023). Assessing the Use of Ustekinumab in a Pediatric Patient With Harlequin Ichthyosis. Cureus, 15(4).
Almuhanna, N., Alrashidi, A. R., Shaheen, E. A., Alanazi, Y., Alfawzan, A., Alharthi, R., & Alhomida, F. A. (2023). Assessing the use of dupilumab in a pediatric patient with bullous congenital ichthyosiform erythroderma. JAAD case reports, 39, 17-20.
Baldo, F., Brena, M., Carbogno, S., Minoia, F., Lanni, S., Guez, S., Petaccia, A., Agostoni, C., Cimaz, R., & Filocamo, G. (2021). Juvenile idiopathic arthritis in Harlequin ichthyosis, a rare combination or the clinical spectrum of the disease? Report of a child treated with etanercept and review of the literature. Pediatric Rheumatology, 19(1), 80.
Barbati, F., Giovannini, M., Oranges, T., Lodi, L., Barni, S., Novembre, E., Baldo, E., Cristofolini, M., Stagi, S., & Ricci, S. (2021). Netherton syndrome in children: management and future perspectives. Frontiers in Pediatrics, 9, 645259.
Blanchet‐Bardon, C., Tadini, G., Machado Matos, M., & Delarue, A. (2012). Association of glycerol and paraffin in the treatment of ichthyosis in children: an international, multicentric, randomized, controlled, double‐blind study. Journal of the European Academy of Dermatology and Venereology, 26(8), 1014-1019.
Cicek, F., Cekic, S., & Kilic, S. S. (2021). Infliximab therapy in an infant with Netherton syndrome. Pediatric dermatology, 38(3), 714-716.
Cortés, H., Del Prado-Audelo, M. L., Urbán-Morlán, Z., Alcalá-Alcalá, S., González-Torres, M., Reyes-Hernández, O. D., González-Del Carmen, M., & Leyva-Gómez, G. (2020). Pharmacological treatments for cutaneous manifestations of inherited ichthyoses. Archives of Dermatological Research, 312, 237-248.
Czarnowicki, T., He, H., Leonard, A., Malik, K., Magidi, S., Rangel, S., Patel, K., Ramsey, K., Murphrey, M., & Song, T. (2018). The major orphan forms of ichthyosis are characterized by systemic T-cell activation and Th-17/Tc-17/Th-22/Tc-22 polarization in blood. Journal of Investigative Dermatology, 138(10), 2157-2167.
Dyer, J. A., Spraker, M., & Williams, M. (2013). Care of the newborn with ichthyosis. Dermatologic Therapy, 26(1), 1-15.
Gulasi, S. (2016). Congenital ichthyosis: a case treated successfully with acitretin. Iranian Journal of Pediatrics, 26(5).
Gutiérrez-Cerrajero, C., Sprecher, E., Paller, A. S., Akiyama, M., Mazereeuw-Hautier, J., Hernández-Martín, A., & González-Sarmiento, R. (2023). Ichthyosis. Nature Reviews Disease Primers, 9(1), 2.
Hernández-Martin, A., Aranegui, B., Martin-Santiago, A., & Garcia-Doval, I. (2013). A systematic review of clinical trials of treatments for the congenital ichthyoses, excluding ichthyosis vulgaris. Journal of the American Academy of Dermatology, 69(4), 544-549. e548.
Huangfu, L., Li, R., Huang, Y., & Wang, S. (2023). The IL-17 family in diseases: From bench to bedside. Signal Transduction and Targeted Therapy, 8(1), 402.
Joosten, M., Clabbers, J., Jonca, N., Mazereeuw-Hautier, J., & Gostyński, A. (2022). New developments in the molecular treatment of ichthyosis: review of the literature. Orphanet journal of rare diseases, 17(1), 269.
Kim, M., Mikhaylov, D., Rangel, S. M., Pavel, A. B., He, H., Renert-Yuval, Y., Del Duca, E., Malik, K., Huynh, T., & Ibler, E. (2022). Transcriptomic analysis of the major orphan ichthyosis subtypes reveals shared immune and barrier signatures. Journal of Investigative Dermatology, 142(9), 2363-2374. e2318.
Lilly, E., & Bunick, C. G. (2023). Congenital Ichthyosis: A Practical Clinical Guide on Current Treatments and Future Perspectives. Clinical, Cosmetic and Investigational Dermatology, 2473-2479.
Martin-García, C., Godoy, E., Cabrera, A., Cañueto, J., Muñoz-Bellido, F. J., Perez-Pazos, J., & Dávila, I. (2023). Report of two sisters with Netherton syndrome successfully treated with dupilumab and review of the literature. International Journal of Immunopathology and Pharmacology, 37, 03946320231172881.
Narbutt, J., Niedźwiedź, M., Lesiak, A., Ceryn, J., & Skibińska, M. (2023). Secukinumab for the treatment of psoriasis in pediatrics: patient selection and acceptability. Patient preference and adherence, 421-431.
Olbrich, H., Sadik, C. D., Ludwig, R. J., Thaçi, D., & Boch, K. (2023). Dupilumab in inflammatory skin diseases: a systematic review. Biomolecules, 13(4), 634.
Paller, A. S. (2019). Profiling immune expression to consider repurposing therapeutics for the ichthyoses. Journal of Investigative Dermatology, 139(3), 535-540.
Paller, A. S., Renert-Yuval, Y., Suprun, M., Esaki, H., Oliva, M., Huynh, T. N., Ungar, B., Kunjravia, N., Friedland, R., & Peng, X. (2017). An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis. Journal of Allergy and Clinical Immunology, 139(1), 152-165.
Palmer, V., & Dunwell, P. (2022). A Case of Ichthyosis Vulgaris and the Use of 70% Glycolic Acid Chemical Peels for Management. Cureus, 14(9).
Peña-Corona, S. I., Echeverria, M. d. l. D. C., Cortés, H., Carmen, G.-D., & Leyva-Gómez, G. (2023). Advances in the treatment of autosomal recessive congenital ichthyosis, a look towards the repositioning of drugs. Frontiers in pharmacology, 14, 1274248.
Pontello, E., Battajon, N., Tormena, F., Giovannini, M., Buffo, M., Mainini, N., Visintin, G., Favero, V., Vendramin, S., & Galeazzo, B. (2020). Congenital ichthyosis in newborns. A case-series and review of the literature. European Journal of Pediatric Dermatology, 30(2), 104-110.
Pontone, M., Giovannini, M., Filippeschi, C., Oranges, T., Pedaci, F. A., Mori, F., Barni, S., Barbati, F., Consonni, F., & Indolfi, G. (2022). Biological treatments for pediatric Netherton syndrome. Frontiers in Pediatrics, 10, 1074243.
Roda, Â., Mendonça-Sanches, M., Travassos, A. R., Soares-de-Almeida, L., & Metze, D. (2017). Infliximab therapy for Netherton syndrome: a case report. JAAD case reports, 3(6), 550-552.
Sethuraman, G., Marwaha, R. K., Challa, A., Yenamandra, V. K., Ramakrishnan, L., Thulkar, S., & Sharma, V. K. (2016). Vitamin D: a new promising therapy for congenital ichthyosis. Pediatrics, 137(1).
Sticherling, M. (2020). Dermatology Part 2: Ichthyoses and Psoriasis. Pediatric Pharmacotherapy, 153-175.
Takhtarova, T. G., Khismatullina, Z. R., Panova, L. D., & Panova, A. N. (2021). Ichthyosis (concept, pathohistology, clinical picture, treatment). Vestnik dermatologii i venerologii, 97(3), 6-13.
Wang, M., Zhai, X., Li, J., Guan, J., Xu, S., Li, Y., & Zhu, H. (2021). The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors. Frontiers in immunology, 12, 670391.
Yogarajah, J., Gouveia, C., Iype, J., Häfliger, S., Schaller, A., Nuoffer, J.-M., Fux, M., & Gautschi, M. (2021). Efficacy and safety of secukinumab for the treatment of severe ABCA12 deficiency‐related ichthyosis in a child. Skin Health and Disease, 1(2), e25.
Zaenglein, A. L., Levy, M. L., Stefanko, N. S., Benjamin, L. T., Bruckner, A. L., Choate, K., Craiglow, B. G., DiGiovanna, J. J., Eichenfield, L. F., & Elias, P. (2021). Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. Pediatric dermatology, 38(1), 164-180.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Eiman Hamza Ahmed Elsayed, Rabab Elsayed Ali Hassan Khater
This work is licensed under a Creative Commons Attribution 4.0 International License.
